FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:358-359 February 3, 2000 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lowenberg, B. PubMed Citation

To the Editor: In their otherwise informative review of new developments in the diagnosis and treatment of acute myeloid leukemia (AML), Löwenberg and colleagues (Sept. 30 issue)¹ state that before the 1970s, the five-year survival rate among patients with AML was less than 15 percent but that survival among patients under the age of 65 years is currently 40 percent. These statistics differ markedly from U.S. population–based survival rates among patients with AML from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute,² a consortium of 11 geographically defined cancer registries. Data from the SEER program . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.